The withdrawal of the FDA accelerated approval for locally advanced or metastatic urothelial carcinoma, a type of bladder ...

Trodelvy’s next big readout is EVOKE-03, which is testing the Gilead drug with Merck’s PD-1 inhibitor Keytruda in PD-L1-high ...

Biotech firm Gilead Sciences has announced plans to voluntarily withdraw the US accelerated approval for Trodelvy ...

Gilead Sciences is set to withdraw Trodelvy's accelerated approval for metastatic urothelial cancer following unsatisfactory ...

Gilead Sciences said on Friday it was voluntarily withdrawing the U.S. approval for Trodelvy in previously treated patients ...

Gilead Sciences is voluntarily withdrawing cancer drug Trodelvy from the U.S. market as a treatment for advanced cases of urothelial carcinoma, a move that comes nearly five months after the ...

Leerink has upgraded Gilead Sciences (NASDAQ:GILD) to outperform, citing the growth outlook for its PrEP treatment ...

Sacituzumab govitecan's (Trodelvy) accelerated approval in urothelial cancer will be voluntarily withdrawn, Gilead Sciences ...

Bengaluru: Gilead Sciences said on Friday it was voluntarily withdrawing its drug, Trodelvy, for previously treated patients ...

Despite the recent setback with Trodelvy's mUC indication, Gilead Sciences (NASDAQ:GILD) continues to demonstrate financial strength and market resilience. According to InvestingPro data ...

On Friday, Gilead Sciences, Inc. (NASDAQ:GILD) announced plans to voluntarily withdraw the U.S. accelerated approval for Trodelvy (sacituzumab govitecan-hziy; SG) for adult patients with locally ...

On Friday, Gilead Sciences (NASDAQ:GILD) maintained its Buy rating and $85.00 stock price target from TD Cowen, despite the pharmaceutical company's decision to voluntarily withdraw mUC indication ...